| Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ... Science 359 (6371), 91-97, 2018 | 4367 | 2018 |
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota M Vétizou, JM Pitt, R Daillère, P Lepage, N Waldschmitt, C Flament, ... Science 350 (6264), 1079-1084, 2015 | 3064 | 2015 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1818 | 2020 |
| Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and-extrinsic factors JM Pitt, M Vétizou, R Daillère, MP Roberti, T Yamazaki, B Routy, ... Immunity 44 (6), 1255-1269, 2016 | 930 | 2016 |
| Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer L Derosa, MD Hellmann, M Spaziano, D Halpenny, M Fidelle, H Rizvi, ... Annals of Oncology 29 (6), 1437-1444, 2018 | 749 | 2018 |
| Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects R Daillère, M Vétizou, N Waldschmitt, T Yamazaki, C Isnard, ... Immunity 45 (4), 931-943, 2016 | 747 | 2016 |
| Anticancer effects of the microbiome and its products L Zitvogel, R Daillère, MP Roberti, B Routy, G Kroemer Nature Reviews Microbiology 15 (8), 465-478, 2017 | 473 | 2017 |
| Microbiome and anticancer immunosurveillance L Zitvogel, M Ayyoub, B Routy, G Kroemer Cell 165 (2), 276-287, 2016 | 439 | 2016 |
| The gut microbiota influences anticancer immunosurveillance and general health B Routy, V Gopalakrishnan, R Daillère, L Zitvogel, JA Wargo, G Kroemer Nature Reviews Clinical Oncology 15 (6), 382-396, 2018 | 423 | 2018 |
| Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer L Derosa, B Routy, AM Thomas, V Iebba, G Zalcman, S Friard, J Mazieres, ... Nature medicine 28 (2), 315-324, 2022 | 257 | 2022 |
| Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ... Nature medicine 27 (8), 1432-1441, 2021 | 247 | 2021 |
| Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage A Fluckiger, R Daillère, M Sassi, BS Sixt, P Liu, F Loos, C Richard, ... Science 369 (6506), 936-942, 2020 | 247 | 2020 |
| Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients L Derosa, B Routy, M Fidelle, V Iebba, L Alla, E Pasolli, N Segata, ... European urology 78 (2), 195-206, 2020 | 227 | 2020 |
| Moving towards personalized treatments of immune-related adverse events K Esfahani, A Elkrief, C Calabrese, R Lapointe, M Hudson, B Routy, ... Nature reviews Clinical oncology 17 (8), 504-515, 2020 | 218 | 2020 |
| The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non–small cell lung cancer T Hakozaki, C Richard, A Elkrief, Y Hosomi, M Benlaïfaoui, I Mimpen, ... Cancer Immunology Research 8 (10), 1243-1250, 2020 | 184 | 2020 |
| The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? A Elkrief, L Derosa, G Kroemer, L Zitvogel, B Routy Annals of Oncology 30 (10), 1572-1579, 2019 | 184 | 2019 |
| The kynurenine pathway is a double-edged sword in immune-privileged sites and in cancer: implications for immunotherapy JP Routy, B Routy, GM Graziani, V Mehraj International Journal of Tryptophan Research 9, IJTR. S38355, 2016 | 184 | 2016 |
| Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors A Elkrief, L El Raichani, C Richard, M Messaoudene, W Belkaid, J Malo, ... Oncoimmunology 8 (4), e1568812, 2019 | 169 | 2019 |
| Immunological off-target effects of imatinib L Zitvogel, S Rusakiewicz, B Routy, M Ayyoub, G Kroemer Nature Reviews Clinical Oncology 13 (7), 431-446, 2016 | 156 | 2016 |
| Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy JD Fumet, C Richard, F Ledys, Q Klopfenstein, P Joubert, B Routy, ... British journal of cancer 119 (8), 950-960, 2018 | 149 | 2018 |
